Klin Padiatr 2020; 232(02): 93-94
DOI: 10.1055/s-0040-1701854
PW I-V
Guided Poster Walk
© Georg Thieme Verlag KG Stuttgart · New York

Nodular Lymphocyte Predominant Hodgkin Lymphoma - experience of Polish Pediatric Leukemia/Lymphoma Study Group

T Klekawka
1   Department of Pediatric Oncology and Hematology, Jagiellonian University Medical College, Kraków, Poland
,
A Moryl-Bujakowska
2   Department of Pediatric Oncology and Hematology, University Children’s Hospital of Krakow, Kraków, Poland
,
K Smalisz
3   Department of Pediatrics, Hematology and Oncology,Warsaw Medical University, Warsaw, Poland
,
A Brozyna
4   Department of Oncology, Children’s Memorial Health Institute, Warsaw, Poland
,
J Kwasnicka
5   Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wroclaw Medical University, Wroclaw, Poland
,
R Chaber
6   Clinical Hospital of Rzeszow, Oncohematology Clinic, Rzeszow, Poland
,
I Ruranska
7   Department of Pediatric Hematology and Oncology, Silesian Medical University, Zabrze, Poland
,
A Wziatek
8   Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland
,
M Mitura-Lesiuk
9   Department of Children’s Hematology and Oncology, Medical University, Lublin, Poland
,
T Stachowicz-Stencel
10   Department of Children’s Oncology and Hematology, Medical University, Gdansk, Poland
,
A Koltan
11   Department of Pediatric Oncology and Hematology, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland
,
K Muszynska-Roslan
12   Department of Children’s Oncology, Medical University, Bialystok, Poland
,
M Stolarska
13   Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University, Medical University, Lodz, Poland
,
A Mizia-Malarz
14   Hematology and Chemotherapy Unit, Pediatric Department, Silesian Medical University, Oncology, Katowice, Poland
,
M Woszczyk
15   Hematology and Oncology Department, Children’s Hospital of Chorzow, Chorzow, Poland
,
A Urbanek-Dadela
16   Pediatric Oncology and Hematology Department, Children’s Hospital of Kielce, Kielce, Poland
,
B Przybyszewski
17   Pediatric Oncology and Hematology Department, Regional Specialized Children’s Hospital in Olsztyn, Olsztyn, Poland
,
K Zielezinska
18   Department of Pediatrics, Oncology and Hematology, Pomeranian Medical University, Szczecin, Poland
,
W Balwierz
1   Department of Pediatric Oncology and Hematology, Jagiellonian University Medical College, Kraków, Poland
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2020 (online)

Also available at
 
 

    Introduction Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLP-HL) is a rare clinical entity. In order to investigate NLP-HL clinical course and treatment a survey was performed within Polish Pediatric Leukemia/Lymphoma Study Group participating centers.

    Methods Questionnaire was sent to all participating centers and data regarding patients, diagnosis, treatment and treatment results were gained. Analysis of collected data was performed.

    Results From 2010 to 2019, 28 pediatric patients with NLP-HL were registered in Poland. Two patients with inherited immune deficiencies and 3 patients who did not complete treatment were excluded from analysis. Age of patients was 5,5 – 17,8 (median: 12,2) years. NLP-HL occurred mainly in males (n=21). All stages of disease were observed but stage I (n=7) and stage II (n=10) were predominating. In most of patients (n=15) supradiaphragmatic localization was observed while mediastinal involvement was observed only in 2 patients.

    7 patients presented with localized, resectable disease. In 3 patients total primary resection was performed. One of these patients relapsed and was treated with CVP chemotherapy. Two patients received further chemotherapy after total resection. Two patients were resected incompletely thus underwent CVP chemotherapy. No other relapses were observed.

    Fourteen patients presented with unresectable disease, of these 8 received CVP chemotherapy, and 6 were treated with other chemotherapy regimens, three relapses were observed and these patients were further treated with chemotherapy and rituximab. One patient underwent auto-SCT. All patients remain alive. Three-years disease-free survival was 81%.

    Conclusion NLP-HL treatment result are consistent with results noted in other countries, but still there is a need for improvement and coherent treatment of NLP-HL patients in Poland. Focus has to be made on primary resection eligible patients. In higher stages of disease consensus on treatment has worked out as many different chemotherapy schedules were in use.


    #